Neurocrine Biosciences generated $959 million in Q2 2026 revenue with 39% year-over-year growth. The company's flagship drug Ingrezza continues strong double-digit growth, while newer treatments Crenessity and Vykat XR are expanding rapidly. With late-stage clinical trials for depression and schizophrenia treatments expected in 2027, analysts project the company could reach $6-7 billion in annual revenue by 2031, though success depends on pipeline candidates and managing pricing pressures.
Axe note: Neurocrine’s rapid expansion looks promising, but South African investors should weigh currency risks and pipeline uncertainties.